Evidence map›Paper›PMID 40754800›Full record

ArticleJournal of Alzheimer's disease : JAD2025

Screening antiseizure medications to break the cycle between neuronal hyperexcitability and Alzheimer's disease.

Aaron J Barbour

Abstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Aaron J BarbourDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-4880-6797

Funding

Seizure-induced enhancement of synaptic signaling regulating tau transmissibility in Alzheimer's DiseaseR01AG077692 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Frances E Jensen, Delia Talos · 2022 to 2026
$3.5M
NIA NIH HHS R01 AG077692
6 · The paper itself

Abstract

Epilepsy is commonly comorbid with Alzheimer's disease and is now well established to accelerate disease course. In the present study, Knox and colleagues evaluated the efficacy of several antiseizure medications (ASMs) in mitigating seizure induction in two aged Alzheimer's disease mouse models with distinct etiologies. They found differential responses to seizure induction and ASM treatment across sexes and models. These results reveal a complex interplay between sex, Alzheimer's disease risk genes, and neuronal hyperexcitability that suggest a tailored approach to seizure control may maximize therapeutic benefit in Alzheimer's disease.

Indexed as

Alzheimer DiseaseAnticonvulsantsNeuronsSeizuresAnimalsDisease Models, AnimalFemaleHumansMaleMiceAnticonvulsantsAlzheimer's diseaseseizuressex differences

Identifiers

PMID40754800
PMCPMC12449591

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.